Hypercalcemia Treatment Market: Global Market to Register Value CAGR of 11.2% by 2026: Global Industry Analysis & Opportunity Assessment, 2016-2026
- REP-GB-1320
- 2016-09-27
- Category: Healthcare, Pharmaceuticals and Medical devices
- 135 Pages
- Format:
Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.
Early diagnosis of hypercalcemia by hydration and treatment with agents – to decrease serum calcium concentrations – also known as hypocalcemic drugs can produce symptomatic improvements within three to five days. The scope of hypercalcemia treatment market study is for Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics for treatment of malignancy-related hypercalcemia.
Market Dynamics
Primary factors fuelling demand for hypercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, growing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternatives over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure.
Market Segmentation by Product Type
Based on product type, the market has been segmented into Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics.
Market Segmentation by Distribution Channel
Revenue from the independent pharmacy and drug stores segment is expected to grow at a very fast pace, and contribute significantly towards distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.
Market Value and Forecast
Global hypercalcemia treatment market revenue is projected to expand at a CAGR of 11.2% during forecast period 2016–2026, and a reach a value of US$ 25,230.2 Mn by the end of 2026.
Key Regions
The global hypercalcemia treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016 end, with revenue contribution expected to expand at a CAGR of 11.4% over the forecast period. Also, North America is estimated to witness comparatively faster growth in terms of revenue over the forecast period. Western Europe hypercalcemia treatment market is expected to register a CAGR of 11.3% in revenue terms over the forecast period. Bisphosphonates segment revenue in the North America hypercalcemia treatment market is expected to register a CAGR of 11.3% over the forecast period, with growth driven by increasing prevalence of cancer and myeloma among the populace in the region.
Key Players
Some key players in the global hypercalcemia treatment market that have been identified in this report include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd. and Cipla Inc. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.
This report by Future Market Insights (FMI) examines the ‘Hypercalcemia Treatment Market’ for the period 2016-2026. The primary objective of the report is to offer updates and information related to market opportunities in the global hypercalcemia treatment market.
The global hypercalcemia treatment market report begins by defining hypercalcemia treatment and various types of products used in hypercalcemia treatment. It is followed by an overview of market dynamics of the global hypercalcemia treatment market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities that are influencing growth of the global hypercalcemia treatment market. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global hypercalcemia treatment market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the market.
Primary factors fuelling demand for hypercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, increasing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternative over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure. However, primary factors hampering growth of the hypercalcemia treatment market are patient location, hypercalcemia drug adoption and cost recovery from limited patient population.
Based on product type, the market has been segmented bisphosphonates (clodronate, etidronate, ibandronate, pamidronate and zoledronic acid), calcitonin, glucocorticoids, denosumab and calcimimetics. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.
Based on distribution channel, the market has been segmented into hospitals, clinics and independent pharmacy and drug stores. Our analysis predicts that revenue form the independent pharmacy and drug stores segment will expand at a relatively fast pace, and the segment is expected to contribute significantly towards the distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.
The next section of the report highlights hypercalcemia treatment market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to revenue growth of the global hypercalcemia treatment market, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa (MEA).
The above sections - by product type, distribution channel and region — evaluate the present scenario and growth prospects of the hypercalcemia treatment market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2026.
To ascertain hypercalcemia treatment market size, we have also considered revenue generated by companies operating in the hypercalcemia treatment market space. The forecast presented here assesses the total revenue by value across the hypercalcemia treatment market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the hypercalcemia treatment market is expected to develop in future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis based on supply side, downstream industry demand and the economic envelope.
In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecast in terms of CAGR, but also analyse on the basis of key parameters such as Year-on-Year (Y-o-Y) growth rates. This is imperative to understand the predictability of the market and to identify the right opportunities across the global hypercalcemia treatment market.
The hypercalcemia treatment market has been segmented on the basis of product type, distribution channel and region. These segments are analysed in terms of Basis Point Share (BPS) to understand each individual segment’s relative contribution to market growth. This detailed level of information is important for identifying various key trends in the global hypercalcemia treatment market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is normally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective.
To understand key segments in terms of growth and adoption for hypercalcemia treatment drugs globally, FMI has developed the hypercalcemia treatment market ‘Attractiveness Index’. The resulting index is expected to help providers identify real market opportunities in the global hypercalcemia treatment market.
In the final section of the report on the global hypercalcemia treatment market, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of drug developers in the hypercalcemia treatment market space and key differentiators. Key categories of providers covered in the report are companies developing hypercalcemia treatment drugs. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the hypercalcemia treatment value chain and the potential players for the same. Report audiences can gain segment-specific company insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in hypercalcemia treatment marketplace.
Detailed profiles of the hypercalcemia treatment developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis and recent developments in the global hypercalcemia treatment market.
Key companies covered in report are Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd. and Cipla Inc.
Key Segments Covered
-
By Product Type
-
Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
-
Bisphosphonates
-
By End-User
- Hospitals
- Clinics
- Independent Pharmacy and Drug Stores
Key Regions/Countries Covered
-
North America
- U.S.
- Canada
-
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
-
Western Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Nordic countries
- Rest of Western Europe
-
Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
-
Asia Pacific Ex. Japan (APEJ)
- China
- India
- Australia and New Zealand
- ASEAN
- Rest of APAC
- Japan
-
Middle East & Africa
- GCC
- South Africa
- North Africa
- Rest of MEA
Key Companies
- Bayer Pharma AG
- Sun Pharmaceutical Industries Ltd.
- Mylan N.V.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Reddy’s Laboratories Ltd.
- Cipla Inc.
Hypercalcemia Treatment Market Reports - Table of Contents
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Hypercalcemia Treatment Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
5. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Product Type
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Product Type
5.3. Y-o-Y Growth Projections By Product Type
5.4. Market Value Forecast By Product Type , 2014–2026
5.4.1. Bisphosphonates
5.4.1.1. Clodronate
5.4.1.2. Etidronate
5.4.1.3. Ibandronate
5.4.1.4. Pamidronate
5.4.1.5. Zoledronic acid
5.4.2. Calcitonin
5.4.3. Glucocorticoids
5.4.4. Denosumab
5.4.5. Calcimimetics
5.5. Prominent Trends
5.6. Market Attractiveness By Product Type
6. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Distribution Channel
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Distribution Channel
6.3. Y-o-Y Growth Projections By Distribution Channel
6.4. Market Value Forecast By Distribution Channel , 2014–2026
6.4.1. Hospitals
6.4.2. Clinics
6.4.3. Independent Pharmacy and Drug Stores
6.5. Prominent Trends
6.6. Market Attractiveness By Distribution Channel
7. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Region
7.1. Basis Point Share (BPS) Analysis By Region
7.2. Y-o-Y Growth Projections By Region
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. APEJ
7.3.6. Japan
7.3.7. MEA
7.4. Market Attractiveness By Country/Region
8. North America Hypercalcemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis By Country
8.1.2. Y-o-Y Growth Projections By Country
8.2. Market Value Forecast By Product Type , 2014–2026
8.2.1. Bisphosphonates
8.2.1.1. Clodronate
8.2.1.2. Etidronate
8.2.1.3. Ibandronate
8.2.1.4. Pamidronate
8.2.1.5. Zoledronic acid
8.2.2. Calcitonin
8.2.3. Glucocorticoids
8.2.4. Denosumab
8.2.5. Calcimimetics
8.3. Market Value Forecast By Distribution Channel , 2014–2026
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Independent Pharmacy and Drug Stores
8.4. Market Value Forecast By Country , 2014–2026
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product Type
8.5.2. By Distribution Channel
8.5.3. By Country
8.6. Prominent Trends
8.7. Drivers and Restraints: Impact Analysis
9. Latin America Hypercalcemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Product Type , 2014–2026
9.2.1. Bisphosphonates
9.2.1.1. Clodronate
9.2.1.2. Etidronate
9.2.1.3. Ibandronate
9.2.1.4. Pamidronate
9.2.1.5. Zoledronic acid
9.2.2. Calcitonin
9.2.3. Glucocorticoids
9.2.4. Denosumab
9.2.5. Calcimimetics
9.3. Market Value Forecast By Distribution Channel , 2014–2026
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Independent Pharmacy and Drug Stores
9.4. Market Value Forecast By Country , 2014–2026
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Argentina
9.4.4. Rest Of Latin America
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
9.6. Prominent Trends
9.7. Drivers and Restraints: Impact Analysis
10. Western Europe Hypercalcemia Treatment Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2.Market Value Forecast By Product Type , 2014–2026
10.2.1. Bisphosphonates
10.2.1.1. Clodronate
10.2.1.2. Etidronate
10.2.1.3. Ibandronate
10.2.1.4. Pamidronate
10.2.1.5. Zoledronic acid
10.2.2. Calcitonin
10.2.3. Glucocorticoids
10.2.4. Denosumab
10.2.5. Calcimimetics
10.3.Market Value Forecast By Distribution Channel , 2014–2026
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Independent Pharmacy and Drug Stores
10.4.Market Value Forecast By Country , 2014–2026
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Nordic countries
10.4.7. Rest Of Western Europe
10.5.Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country
10.6. Prominent Trends
10.7. Drivers and Restraints: Impact Analysis
11. Eastern Europe Hypercalcemia Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.2.Market Value Forecast By Product Type , 2014–2026
11.2.1. Bisphosphonates
11.2.1.1. Clodronate
11.2.1.2. Etidronate
11.2.1.3. Ibandronate
11.2.1.4. Pamidronate
11.2.1.5. Zoledronic acid
11.2.2. Calcitonin
11.2.3. Glucocorticoids
11.2.4. Denosumab
11.2.5. Calcimimetics
11.3.Market Value Forecast By Distribution Channel , 2014–2026
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Independent Pharmacy and Drug Stores
11.4.Market Value Forecast By Country , 2014–2026
11.4.1. Russia
11.4.2. Poland
11.4.3. Rest Of Eastern Europe
11.5.Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country
11.6. Prominent Trends
11.7. Drivers and Restraints: Impact Analysis
12. APEJ Hypercalcemia Treatment Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2.Market Value Forecast By Product Type , 2014–2026
12.2.1. Bisphosphonates
12.2.1.1. Clodronate
12.2.1.2. Etidronate
12.2.1.3. Ibandronate
12.2.1.4. Pamidronate
12.2.1.5. Zoledronic acid
12.2.2. Calcitonin
12.2.3. Glucocorticoids
12.2.4. Denosumab
12.2.5. Calcimimetics
12.3.Market Value Forecast By Distribution Channel , 2014–2026
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Independent Pharmacy and Drug Stores
12.4.Market Value Forecast By Country , 2014–2026
12.4.1. China
12.4.2. India
12.4.3. ASEAN
12.4.4. Australia & New Zealand
12.4.5. Rest Of APEJ
12.5.Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country
12.6. Prominent Trends
12.7. Drivers and Restraints: Impact Analysis
13. Japan Hypercalcemia Treatment Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2.Market Value Forecast By Product Type , 2014–2026
13.2.1. Bisphosphonates
13.2.1.1. Clodronate
13.2.1.2. Etidronate
13.2.1.3. Ibandronate
13.2.1.4. Pamidronate
13.2.1.5. Zoledronic acid
13.2.2. Calcitonin
13.2.3. Glucocorticoids
13.2.4. Denosumab
13.2.5. Calcimimetics
13.3.Market Value Forecast By Distribution Channel , 2014–2026
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Independent Pharmacy and Drug Stores
13.4.Market Attractiveness Analysis
13.4.1. By Product Type
13.4.2. By Distribution Channel
13.5. Prominent Trends
13.6. Drivers and Restraints: Impact Analysis
14. MEA Hypercalcemia Treatment Market Analysis and Forecast
14.1.Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.2.Market Value Forecast By Product Type , 2014–2026
14.2.1. Bisphosphonates
14.2.1.1. Clodronate
14.2.1.2. Etidronate
14.2.1.3. Ibandronate
14.2.1.4. Pamidronate
14.2.1.5. Zoledronic acid
14.2.2. Calcitonin
14.2.3. Glucocorticoids
14.2.4. Denosumab
14.2.5. Calcimimetics
14.3.Market Value Forecast By Distribution Channel , 2014–2026
14.3.1. Hospitals
14.3.2. Clinics
14.3.3. Independent Pharmacy and Drug Stores
14.4.Market Value Forecast By Country , 2014–2026
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. North Africa
14.4.4. Rest Of MEA
14.5.Market Attractiveness Analysis
14.5.1. By Product Type
14.5.2. By Distribution Channel
14.5.3. By Country
14.6. Prominent Trends
14.7. Drivers and Restraints: Impact Analysis
15. Competition Landscape
15.1.Competition Dashboard
15.2.Market Share Analysis By Company (2015)
15.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
15.3.1. Bayer Pharma AG
15.3.2. Sun Pharmaceutical Industries Ltd.
15.3.3. Mylan N.V.
15.3.4. Pfizer Inc.
15.3.5. Amgen Inc.
15.3.6. Novartis AG
15.3.7. Dr. Reddy’s Laboratories Ltd.
15.3.8. Cipla Inc.
16. Assumptions and Acronyms Used
17. Research Methodology
Hypercalcemia Treatment Market Reports - List of Tables
Table 1: Global Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 2: Global Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 3: Global Hypercalcemia Treatment Market Value (US$ Mn) By Region, 2014–2026
Table 4: North America Hypercalcemia Treatment Market Value (US$ Mn) By Country, 2014–2026
Table 5: North America Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 6: North America Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 7: Latin America Hypercalcemia Treatment Market Value (US$ Mn) By Country/Region, 2014–2026
Table 8: Latin America Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 9: Latin America Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 10: Western Europe Hypercalcemia Treatment Market Value (US$ Mn) By Country/Region, 2014–2026
Table 11: Western Europe Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 12: Western Europe Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 13: Eastern Europe Hypercalcemia Treatment Market Value (US$ Mn) By Country/Region, 2014–2026
Table 14: Eastern Europe Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 15: Eastern Europe Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 16: APEJ Hypercalcemia Treatment Market Value (US$ Mn) By Country/Region, 2014–2026
Table 17: APEJ Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 18: APEJ Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 19: Japan Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 20: Japan Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Table 21: MEA Hypercalcemia Treatment Market Value (US$ Mn) By Country/Region, 2014–2026
Table 22: MEA Hypercalcemia Treatment Market Value (US$ Mn) By Product Type, 2014–2026
Table 23: MEA Hypercalcemia Treatment Market Value (US$ Mn) By Distribution Channel, 2014–2026
Hypercalcemia Treatment Market Reports - List of Figures
Figure 1: Global Hypercalcemia Treatment Market Value (US$ Mn) & Y-o-Y Growth Rate (%), 2014–2026
Figure 2: Global Hypercalcemia Treatment Market Absolute $ Opportunity (US$ Mn), 2014–2026
Figure 3: Global Hypercalcemia Treatment Market Value Share, By Distribution Channel, 2015 & 2026
Figure 4: Global Hypercalcemia Y-o-Y Growth Rate, By Distribution Channel, 2015–2026
Figure 5: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Hospital Distribution Channel, 2014–2026
Figure 6: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Clinics Distribution Channel, 2014–2026
Figure 7: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Independent Pharmacy & Drug Stores Distribution Channel, 2014–2026
Figure 8: Global Hypercalcemia Treatment Market Attractiveness Analysis, By Distribution Channel, 2016–2026
Figure 9: Global Hypercalcemia Treatment Market Value Share, By Product Type, 2015 & 2026
Figure 10: Global Hypercalcemia Y-o-Y Growth Rate, By Product Type, 2015–2026
Figure 11: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Bisphosphonates Product Type, 2014–2026
Figure 12: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Calcitonin Product Type, 2014–2026
Figure 13: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Glucocorticoids Product Type, 2014–2026
Figure 14: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Denosumab Product Type, 2014–2026
Figure 15: Global Hypercalcemia Treatment Market Absolute $ Opportunity, By Calcimimetics Product Type, 2014–2026
Figure 16: Global Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 17: Global Hypercalcemia Treatment Market Value Share, By Region, 2015 & 2026
Figure 18: Global Hypercalcemia Y-o-Y Growth Rate, By Region, 2015–2026
Figure 19: North America Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 20: Latin America Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 21: Western Europe Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 22: Eastern Europe Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 23: APEJ Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 24: Japan Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 25: MEA Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 26: Global Hypercalcemia Treatment Market Attractiveness Analysis, By Region, 2016–2026
Figure 27: North America Hypercalcemia Treatment Market Value Share, By Country, 2015 & 2026
Figure 28: North America Hypercalcemia Y-o-Y Growth Rate, By Country, 2015–2026
Figure 29: U.S. Hypercalcemia Treatment Market Absolute $ Opportunity,
Figure 30: Canada Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 31: North America Hypercalcemia Treatment Market Attractiveness Analysis, By Country, 2016–2026
Figure 32: North America Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 33: North America Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 34: Latin America Hypercalcemia Treatment Market Value Share, By Country/Region, 2015 & 2026
Figure 35: Latin America Hypercalcemia Y-o-Y Growth Rate, By Country/Region, 2015–2026
Figure 36: Brazil Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 37: Mexico Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 38: Argentina Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 39: Rest Of Latin America Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 40: Latin America Hypercalcemia Treatment Market Attractiveness Analysis, By Country/Region, 2016–2026
Figure 41: Latin America Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 42: Latin America Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 43: Western Europe Hypercalcemia Treatment Market Value Share, By Country/Region, 2015 & 2026
Figure 44: Western Europe Hypercalcemia Y-o-Y Growth Rate, By Country/Region, 2015–2026
Figure 45: Germany Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 46: U.K. Hypercalcemia Treatment Market Absolute $ Opportunity,
Figure 47: France Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 48: Nordic countries Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 49: Spain Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 50: Italy Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 51: Rest Of Western Europe Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 52: Western Europe Hypercalcemia Treatment Market Attractiveness Analysis, By Country/Region, 2016–2026
Figure 53: Western Europe Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 54: Western Europe Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 55: Eastern Europe Hypercalcemia Treatment Market Value Share, By Country/Region, 2015 & 2026
Figure 56: Eastern Europe Hypercalcemia Y-o-Y Growth Rate, By Country/Region, 2015–2026
Figure 57: Russia Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 58: Poland Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 59: Rest Of Eastern Europe Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 60: Eastern Europe Hypercalcemia Treatment Market Attractiveness Analysis, By Country/Region, 2016–2026
Figure 61: Eastern Europe Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 62: Eastern Europe Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 63: APEJ Hypercalcemia Treatment Market Value Share, By Country/Region, 2015 & 2026
Figure 64: APEJ Hypercalcemia Y-o-Y Growth Rate, By Country/Region, 2015–2026
Figure 65: China Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 66: India countries Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 67: ASEAN Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 68: Australia & New Zealand Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 69: Rest Of APEJ Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 70: APEJ Hypercalcemia Treatment Market Attractiveness Analysis, By Country/Region, 2016–2026
Figure 71: APEJ Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type,
Figure 72: APEJ Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 73: Japan Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 74: Japan Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type, 2016–2026
Figure 75: Japan Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 76: MEA Hypercalcemia Treatment Market Value Share, By Country/Region, 2015 & 2026
Figure 77: MEA Hypercalcemia Y-o-Y Growth Rate, By Country/Region, 2015–2026
Figure 78: GCC countries Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 79: South Africa Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 80: North Africa Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 81: Rest Of MEA Hypercalcemia Treatment Market Absolute $ Opportunity, 2014–2026
Figure 82: MEA Hypercalcemia Treatment Market Attractiveness Analysis, By Country/Region, 2016–2026
Figure 83: MEA Hypercalcemia Treatment Market Attractiveness Analysis, By Product Type,
Figure 84: MEA Hypercalcemia Treatment Market Attractiveness Analysis, By End User, 2016–2026
Figure 85: Global Hypercalcemia Treatment Market, Company Share Analysis, 2015